精准医学研究进展

被引：39

作者：

何明燕 ^{[1
]}

夏景林 ^{[1
,2
]}

王向东 ^{[3
,4
]}

机构：

[1] 复旦大学附属中山医院肝癌研究所

[2] 复旦大学附属闵行医院

[3] 上海市临床生物信息学研究所

[4] 复旦大学附属中山医院临床生物信息学研究中心

来源：

世界临床药物 | 2015年 / 36卷 / 06期

关键词：

精准医学; 转化医学; 组学; 靶向治疗;

D O I：

10.13683/j.wph.2015.06.012

中图分类号：

R-05 [医学与其他学科的关系];

学科分类号：

1001 ;

摘要：

基于人类基因组计划及二代测序技术获得的大量生物信息学数据,展开人类健康和疾病的相关性研究意义重大。随着新的疾病管理模型-精准医学概念逐步得到认可,依据患者内在生物学信息以及传统临床症状和体征,临床有望针对患者个体实施关于健康医疗和临床决策的量身定制。本文从不同平台组学数据整合标准化模型的建立意义等出发,简要综述有助于精准医疗的基于分子表型的疾病细分以及靶向特异性药物的研发,期待未来靶向药物的研发能针对疾病亚型秉承更加特异和更低毒性的原则展开。

引用

页码：418 / 422

页数：5

共 8 条

[1]

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation[J] . Nan Chen,Wenfeng Fang,Jianhua Zhan,Shaodong Hong,Yanna Tang,Shiyang Kang,Yaxiong Zhang,Xiaobo He,Ting Zhou,Tao Qin,Yan Huang,Xianping Yi,Li Zhang.Journal of Thoracic Oncology . 2015 (6)

[2] Management of Acquired Resistance to Epidermal Growth Factor Receptor Kinase Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer [J].

Sacher, Adrian G. ;

Jaenne, Pasi A. ;

Oxnard, Geoffrey R. .

CANCER, 2014, 120 (15) :2289-2298

[3] Lessons from the Cancer Genome [J].

Garraway, Levi A. ;

Lander, Eric S. .

CELL, 2013, 153 (01) :17-37

[4]

Genomes of 100?000 people will be sequenced to create an open access research resource[J] . Ingrid Torjesen.BMJ . 2013 (nov0)

[5]

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer （EURTAC）: a multicentre, open-label, randomised phase 3 trial[J] . Lancet Oncology . 2012 (3)

[6]

Mapping of the secretome of primary isolates of mammalian cells, stem cells and derived cell lines[J] . HelenaSkalnikova,JanMotlik,Suresh JivanGadher,HanaKovarova.Proteomics . 2011 (4)

[7]

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor （WJTOG3405）: an open label, randomised phase 3 trial[J] . Tetsuya Mitsudomi,Satoshi Morita,Yasushi Yatabe,Shunichi Negoro,Isamu Okamoto,Junji Tsurutani,Takashi Seto,Miyako Satouchi,Hirohito Tada,Tomonori Hirashima,Kazuhiro Asami,Nobuyuki Katakami,Minoru Takada,Hiroshige Yoshioka,Kazuhiko Shibata,Shinzoh Kudoh,Eiji Shimizu,Hiroshi Saito,Shinichi Toyook

[8]

Secreted protein prediction system combining CJ-SPHMM, TMHMM, and PSORT[J] . Yunjia Chen,Peng Yu,Jingchu Luo,Ying Jiang.Mammalian Genome . 2003 (12)

← 1 →